본문 바로가기
KERD
논문KCI 등재

In Vitro and In Vivo Anti-Clostridioides difficile Effect of a Probiotic Bacillus amyloliquefaciens Strain

Seo Hoonhee|Kim Sukyung|Islam Md Imtiazul|Redwan Asma|Lee Saebim|Siddiquee Mashuk|송호연
한국미생물·생명공학회 (The Korean Society For Microbiology And Biotechnology)|2022.01|Journal of Microbiology and Biotechnology|제32권 제1호|pp. 46-55|DOI 10.4014/jmb.2107.07057

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

antibioticBacillus amyloliquefaciensClostridioides difficileprobioticBA PMC-80
주제분류생물학

초록

Clostridioides difficile infection (CDI) is a significant cause of hospital-acquired and antibioticmediated intestinal diseases and is a growing global public health concern. Overuse of antibiotics and their effect on normal intestinal flora has increased the incidence and severity of infections. Thus, the development of new, effective, and safe treatment options is a high priority. Here, we report a new probiotic strain, Bacillus amyloliquefaciens (BA PMC-80), and its in vitro/in vivo anti-C. difficile effect as a prospective novel candidate for replacing conventional antibiotics. BA PMC-80 showed a significant anti-C. difficile effect in coculture assay, and its cell-free supernatant (CFS) also exhibited a considerable anti-C. difficile effect with an 89.06 μg/ml 50% minimal inhibitory concentration (MIC) in broth microdilution assay. The CFS was stable and equally functional under different pHs, heat, and proteinase treatments. It also exhibited a high sensitivity against current antibiotics and no toxicity in subchronic toxicity testing in hamsters. Finally, BA PMC-80 showed a moderate effect in a hamster CDI model with reduced infection severity and delayed death. However, further studies are required to optimize the treatment condition of the hamster CDI model for better efficacy and identify the antimicrobial compound produced by BA PMC-80.

Abstract

Clostridioides difficile infection (CDI) is a significant cause of hospital-acquired and antibioticmediated intestinal diseases and is a growing global public health concern. Overuse of antibiotics and their effect on normal intestinal flora has increased the incidence and severity of infections. Thus, the development of new, effective, and safe treatment options is a high priority. Here, we report a new probiotic strain, Bacillus amyloliquefaciens (BA PMC-80), and its in vitro/in vivo anti-C. difficile effect as a prospective novel candidate for replacing conventional antibiotics. BA PMC-80 showed a significant anti-C. difficile effect in coculture assay, and its cell-free supernatant (CFS) also exhibited a considerable anti-C. difficile effect with an 89.06 μg/ml 50% minimal inhibitory concentration (MIC) in broth microdilution assay. The CFS was stable and equally functional under different pHs, heat, and proteinase treatments. It also exhibited a high sensitivity against current antibiotics and no toxicity in subchronic toxicity testing in hamsters. Finally, BA PMC-80 showed a moderate effect in a hamster CDI model with reduced infection severity and delayed death. However, further studies are required to optimize the treatment condition of the hamster CDI model for better efficacy and identify the antimicrobial compound produced by BA PMC-80.

참고문헌 (60)

  1. Bartlett JG, "Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis", Gastroenterology, 75, pp.778~782 (1978)
  2. McDonald LC, "Clinical practice guidelines for Clostridium difficile infection in adults and children : 2017 update by the Infectious Diseases Society of America(IDSA)and Society for Healthcare Epidemiology of America(SHEA)", Clin. Infect. Dis, 66, pp.1~48 (2018)[DOI]
  3. Colomb-Cotinat M, "Epidemiology of Clostridioides difficile infections, France, 2010 to 2017", Eurosurveillance, 24, pp.1800638~ (2019)
  4. Lessa FC, "Burden of Clostridium difficile Infection in the United States", N. Engl. J. Med, 372, pp.825~834 (2015)
  5. "Antibiotic-resistant Germs: New Threats" (2021)[URL]
  6. Kato H, "Clostridioides(Clostridium)difficile infection burden in Japan : a multicenter prospective study", Anaerobe, 60, pp.102011~ (2019)
  7. Curcio D, "Clostridium difficile-associated diarrhea in developing countries : a systematic review and meta-analysis", Infect. Dis. Ther, 8, pp.87~103 (2019)
  8. Evans CT, "Current trends in the epidemiology and outcomes of Clostridium difficile infection", Clin. Infect. Dis, 60, pp.66~71 (2015)
  9. C.P. Kelly, "Can we identify patients at high risk of recurrent Clostridium difficile infection?", Clinical Microbiology and Infection, 18, pp.21~27 (2012), Elsevier BV[DOI]
  10. Johnson S, "Recurrent Clostridium difficile infection: causality and therapeutic approaches", Int. J. Antimicrob. Agents, 33(Suppl 1), pp.33~36 (2009)
  11. Chai J, "Management of primary and recurrent Clostridium difficile infection : an update", Antibiotics, 7, pp.54~ (2018)
  12. Abougergi MS, "Intravenous immunoglobulin for the treatment of Clostridium difficile infection : a review", Dig. Dis. Sci, 56, pp.19~26 (2011)
  13. Wilcox MH, "Bezlotoxumab for prevention of recurrent Clostridium difficile infection", N. Engl. J. Med, 376, pp.305~317 (2017)
  14. Kociolek LK, "Breakthroughs in the treatment and prevention of Clostridium difficile infection", Nat. Rev. Gastroenterol. Hepatol, 13, pp.150~160 (2016)
  15. Rao K, "Fecal microbiota transplantation for the management of Clostridium difficile infection", Infect. Dis. Clin. North Am, 29, pp.109~122 (2015)
  16. Vyas D, "Fecal transplant policy and legislation", World J. Gastroenterol. WJG, 21, pp.6~11 (2015)
  17. DeFilipp Z, "Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant.", N. Engl. J. Med, 381, pp.2043~2050 (2019)
  18. de Bruyn G, "Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection : a randomized Phase 2 clinical trial", Vaccine, 34, pp.2170~2178 (2016)
  19. KotloffKL, "Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults", Infect. Immun, 69, pp.988~995 (2001)
  20. Stavros Sougioultzis, "Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea", Gastroenterology, 128(3), pp.764~770 (2005), Elsevier BV[DOI]
  21. Greenberg RN, "Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine", Vaccine, 30, pp.2245~2249 (2012)
  22. McFarland LV, "Epidemiology, risk factors and treatments for antibiotic-associated diarrhea", Dig. Dis, 16, pp.292~307 (1998)
  23. Rolfe RD, "The role of probiotic cultures in the control of gastrointestinal health", J. Nutr, 130, pp.396~402 (2000)
  24. Katz JA, "Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea", J. Clin. Gastroenterol, 40, pp.249~255 (2006)
  25. Kotowska M, "Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children : a randomized double-blind placebo-controlled trial", Aliment. Pharmacol. Ther, 21, pp.583~590 (2005)
  26. Basu S, "Effect of Lactobacillus rhamnosus GG in persistent diarrhea in Indian children : a randomized controlled trial", J. Clin. Gastroenterol, 41, pp.756~760 (2007)
  27. Benitez L, "Antimicrobial activity of Bacillus amyloliquefaciens LBM 5006 is enhanced in the presence of Escherichia coli", Curr. Microbiol, 62, pp.1017~1022 (2011)
  28. Marahier MA, "Regulation of peptide antibiotic production in Bacillus", Mol. Microbiol, 7, pp.631~636 (1993)
  29. Stein T, "Bacillus subtilis antibiotics : structures, syntheses and specific functions", Mol. Microbiol, 56, pp.845~857 (2005)
  30. Wu L, "Difficidin and bacilysin from Bacillus amyloliquefaciens FZB42 have antibacterial activity against Xanthomonas oryzae rice pathogens", Sci. Rep, 5, pp.12975~ (2015)
  31. Chen XH, "Difficidin and bacilysin produced by plant-associated Bacillus amyloliquefaciens are efficient in controlling fire blight disease", J. Biotechnol, 140, pp.38~44 (2009)
  32. Kim PI, "Production of an antifungal protein for control of Colletotrichum lagenarium by Bacillus amyloliquefaciens MET0908", FEMS Microbiol. Lett, 234, pp.177~183 (2006)
  33. Wong JH, "An antifungal protein from Bacillus amyloliquefaciens", J. Appl. Microbiol, 105, pp.1888~1898 (2008)
  34. Lisianne Brittes Benitez, "Isolation and Characterization of Antifungal Peptides Produced by Bacillus amyloliquefaciens LBM5006", The Journal of Microbiology, 48(6), pp.791~797 (2010), 한국미생물학회
  35. Khattab RA, "Bacteria producing antimicrobials against Clostridium difficile isolated from human stool", Anaerobe, 63, pp.102206~ (2020)
  36. 조영희, "Isolation and Characterization of Lactic Acid Bacteria from Kimchi, Korean Traditional Fermented Food to Apply into Fermented Dairy Products", 한국축산식품학회지, 33(1), pp.75~82 (2013), 한국축산식품학회[DOI]
  37. 전혜린, "Probiotic characterization of Bacillus subtilis P223 isolated from kimchi", Food Science and Biotechnology, 26(6), pp.1641~1648 (2017), 한국식품과학회[DOI]
  38. Karska-Wysocki B, "Antibacterial activity of Lactobacillus acidophilus and Lactobacillus casei against methicillin-resistant Staphylococcus aureus(MRSA)", Microbiol. Res, 165, pp.674~686 (2010)
  39. Haipeng Cao, "Bacillus amyloliquefaciens G1: A Potential Antagonistic Bacterium against Eel-Pathogenic Aeromonas hydrophila", Evidence-Based Complementary and Alternative Medicine, 2011, pp.1~7 (2011), Hindawi Limited[DOI]
  40. Tamariz-Angeles C, "Isolation and identification of cellulolytic and xylanolytic bacteria from huancarhuaz hot spring, Peru", Annu. Res. Rev. Biol, 4, pp.2920~2930 (2014)
  41. Herlemann DP, "Transitions in bacterial communities along the 2000 km salinity gradient of the Baltic Sea", ISME J, 5, pp.1571~1579 (2011)
  42. 서재구, "In Vitro Evaluation of Antimicrobial Activity of Lactic Acid Bacteria against Clostridium difficile", 한국독성학회지, 29(2), pp.99~106 (2013), 한국독성학회[DOI]
  43. Islam MI, "In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis", Int. J. Antimicrob. Agents, 54, pp.69~74 (2019)
  44. Ben Ayed H, "Acute and sub-chronic oral toxicity profiles of lipopeptides from Bacillus mojavensis A21 and evaluation of their in vitro anticoagulant activity", Chem. Biol. Interact, 236, pp.1~6 (2015)
  45. Sambol SP, "Colonization for the prevention of Clostridium difficile disease in hamsters", J. Infect. Dis, 186, pp.1781~1789 (2002)
  46. S. P. Borriello, "Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis", Journal of Medical Microbiology, 24(1), pp.53~64 (1987), Microbiology Society[DOI]
  47. Trzasko A, "Efficacy of LFF571 in a hamster model of Clostridium difficile infection", Antimicrob. Agents Chemother, 56, pp.4459~4462 (2012)
  48. Adrianne N. Edwards, "Isolating and Purifying Clostridium difficile Spores", Methods in Molecular Biology, pp.117~128 (2016), Springer New York[DOI]
  49. Borah T, "Biocatalysis and agricultural biotechnology probiotic characterization of indigenous Bacillus velezensis strain DU14 isolated from Apong, a traditionally fermented rice beer of Assam", Biocatal. Agric. Biotechnol, 18, pp.101008~ (2019)
  50. Levy DG, "Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting", Clin. Ther, 22, pp.91~102 (2000)
  51. Gao XW, "Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients", Am. J. Gastroenterol, 105, pp.1636~1641 (2010)
  52. Blaabjerg S, "Probiotics for the prevention of antibiotic-associated diarrhea in outpatients—A systematic review and meta-analysis", Antibiotics, 6, pp.21~ (2017)
  53. Monteiro CRAV, "In Vitro antimicrobial activity and probiotic potential of Bifidobacterium and Lactobacillus against species of Clostridium", Nutrients, 11, pp.448~ (2019)
  54. Hu HQ, "Characterization of an antimicrobial material from a newly isolated Bacillus amyloliquefaciens from mangrove for biocontrol of Capsicum bacterial wilt", Biol. Control, 54, pp.359~365 (2010)
  55. Shokryazdan P, "Safety assessment of two new Lactobacillus strains as probiotic for human using a rat model", PLoS One, 11, pp.e0159851~ (2016)
  56. Geeraerts S, "Vegetative Bacillus amyloliquefaciens cells do not confer protection against necrotic enteritis in broilers despite high antibacterial activity of its supernatant against Clostridium perfringens in vitro", Br. Poult. Sci, 57, pp.324~329 (2016)
  57. Ji J, "Probiotic Bacillus amyloliquefaciens SC06 prevents bacterial translocation in weaned mice", Indian J. Microbiol, 53, pp.323~328 (2013)
  58. Hairul Islam VI, "Isolation and characterization of putative probiotic bacterial strain, Bacillus amyloliquefaciens, from north east Himalayan soil based on in vitro and in vivo functional properties", Probiotics Antimicrob. Proteins, 3, pp.175~185 (2011)
  59. S Geeraerts, "Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model", J. Gastroenterol. Hepatol, 30, pp.1275~1280 (2015)
  60. Abutaleb NS, "In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection", Sci. Rep, 11, pp.7093~ (2021)

관련 논문AI추천

Efficacy Assessment of the Co-Administration of Vancomycin and Metronidazole in Clostridioides difficile -Infected Mice Based on Changes in Intestinal EcologyHuang He, Yang Jingpeng, Zhong Saiwei한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2024 · 제34권 제4호Antimicrobial and Immunomodulatory Effects of Bifidobacterium Strains: A Review신혜순, 임현정한국미생물·생명공학회 · Journal of Microbiology and Biotechnology2020 · 제30권 제12호Properties of Antimicrobial Substances Produced by Bacillus amyloliquefaciens CJW15 and Bacillus amyloliquefaciens SSD8김정환, 김현진, 심재민, 야오좡, 이강욱, 이재용, 함경식, 류샤오밍한국미생물·생명공학회 · 한국미생물·생명공학회지2016 · 제44권 제1호Antimicrobial Activities and Probiotic Properties of Bacillus sp. Strains Isolated from Fermented Cooked RiceKhatun Maya, Rahman Md. Ajijur, Sultana Mst. Sarmin한국미생물·생명공학회 · 한국미생물·생명공학회지2024 · 제52권 제3호Properties of Antimicrobial Substances Produced by Bacillus species Isolated from Rice Straw김정환, 김현진, 심재민, 이강욱, Xiaoming Liu, Zhuang Yao한국미생물·생명공학회 · 한국미생물·생명공학회지2017 · 제45권 제2호Comparison of Supplemented Brucella Agar and Modified Clostridium difficile Agar for Antimicrobial Susceptibility Testing of Clostridium difficile강정옥, 김계형, 김지은, 배현주대한진단검사의학회 · Annals of Laboratory Medicine2014 · 제34권 제6호

이 간행물의 다른 논문 (14건)

COVID-19 Drug Development김승택pp. 1-5A Brucella Omp16 Conditional Deletion Strain Is Attenuated in BALB/c MiceWang Aihua, Jin Yaping, Zhou Dong, Zhang Guangdong, Li Junmei, Zheng Weifang, Fang Jiaoyang, Zhi Feijiepp. 6-14A Newly Synthesized Flavone from Luteolin Escapes from COMT-Catalyzed Methylation and Inhibits Lipopolysaccharide-Induced Inflammation in RAW264.7 Macrophages via JNK, p38 and NF-κB Signaling PathwaysSun Zhi-qin, Xin Yang, Ye Lin, Wu Zhi-yuan, Sun Hai-jian, Huang De-jianpp. 15-26Novel Polyhydroxybutyrate-Degrading Activity of the Microbulbifer Genus as Confirmed by Microbulbifer sp. SOL03 from the Marine Environment양영헌, Ham Sion, Suha Min Ju, Kim Sang Hyun, Gurav Ranjit, Lee Hong-Ju, Cho Jang Yeon, Park Sol Lee, BHATIA SHASHI KANT, Kim Su Hyun, Park Kyungmoon, Park See-Hyoung, 김윤곤pp. 27-36Myricetin Disturbs the Cell Wall Integrity and Increases the Membrane Permeability of Candida albicans이흥식, 김연희pp. 37-45
원문 보기